Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announces that the special meeting of its securityholders to be held this Monday, December 11, 2023 at 9:30 a.m. (Vancouver time) (the “Special Meeting“) to approve, among other things, the Company’s proposed arrangement (the “Arrangement“) under Part 9, Division 5 of the Business Corporations Act (British Columbia) (the “Act“) has been adjourned.
The Special Meeting has been adjourned in accordance with the interim order of the Supreme Court of British Columbia made pursuant to the Act in connection with the Arrangement (the “Interim Order“).
In accordance with the Articles of the Company and the terms of the Interim Order, the adjourned Special Meeting will be reconvened at the offices of Fasken Martineau DuMoulin LLP at 550 Burrard Street, Suite 2900, Vancouver, British Columbia V6C 0A3 on Monday, December 18, 2023, at 9:30 a.m. (Vancouver time).
The Special Meeting has been adjourned due to the requirement for the Company to restructure the terms of its financing of senior secured convertible notes to Helena Global Investment Opportunities 1 Ltd., an affiliate of Helena Partners Inc. (“Helena“), as previously described in the Company’s press release dated December 6, 2023 (the “Note Financing“), in order to ensure the Company meets certain NASDAQ listing requirements. The Company anticipates that it will announce the amended terms of the Note Financing on or before the date of the reconvened Special Meeting.
“I’m looking forward to continuing to work closely with the Filament and Jupiter teams as we work to structure the terms of our investment to meet the requirements of all parties, including the NASDAQ exchange.”
-Jeremy Weech, Helena Managing Partner.
For additional details regarding the previously announced business combination among Filament, Jupiter Acquisition Corporation (NASDAQ:JAQC), a special purpose acquisition company, and 1427702 B.C. Ltd. (such business combination, the “Proposed Business Combination“), please see the sources described below under, “Important Information About the Proposed Business Combination and Where to Find It.”
ABOUT FILAMENT HEALTH CORP (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.
ABOUT HELENA PARTNERS INC.
Helena Partners Inc. is a Cayman Islands-based investment vehicle and advisor focused on providing listed companies around the world with growth capital. Helena invests across the capital stack in the form of debt, equity, and equity-linked investments.